Please enable JavaScript to continue using this application.

Compare $KROS vs $TLSI | Chartloom

Compare

$KROS vs $TLSI

Keros Therapeutics Inc · TriSalus Life Sciences Inc

KROS

Keros Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Compare $KROS vs $TLSI

Comparing Keros Therapeutics Inc and TriSalus Life Sciences Inc

KROSKeros Therapeutics Inc

TLSITriSalus Life Sciences Inc

KROSKeros Therapeutics Inc

Market cap

$236M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.6%

YTD performance

-35.5%

52W performance

-25.1%

FCF yield

-20.5%

TLSITriSalus Life Sciences Inc

Market cap

$249M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.61x

Rev growth (TTM)

25.2%

YTD performance

-33.4%

52W performance

-16.3%

FCF yield

-9.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KROS

TLSI

Detailed metrics comparison

KROS

Keros Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Market Cap

KROS$236M

TLSI$249M

Enterprise Value

KROS$-21M

TLSI$236M

Price

KROS$11.95

TLSI$4.06

P/E Ratio

KROSN/A

TLSIN/A

P/S Ratio

KROS15.75x

TLSI5.53x

EV/Sales

KROS-1.41x

TLSI5.24x

EV/EBITDA

KROS-0.47x

TLSI0.00x

P/B Ratio

KROS0.86x

TLSI40.61x

P/FCF Ratio

KROSN/A

TLSIN/A

EV/FCF

KROS0.44x

TLSI-10.14x

PEG Ratio

KROSN/A

TLSIN/A

Forward P/E (NTM)

KROSN/A

TLSIN/A

Forward P/S (NTM)

KROSN/A

TLSI3.61x

Revenue (TTM)

KROS$15M

TLSI$45M

Revenue Growth (YoY)

KROS-93.6%

TLSI25.2%

Forward Rev Growth

KROS-96.3%

TLSI40.1%

Gross Margin (TTM)

KROS0.0%

TLSI85.8%

Operating Margin (TTM)

KROS0.0%

TLSI0.0%

EBITDA Margin (TTM)

KROS-665.2%

TLSI-66.4%

Net Margin (TTM)

KROS-553.9%

TLSI-130.2%

FCF Margin (TTM)

KROS-322.9%

TLSI-51.6%

Net Income (TTM)

KROS$-83M

TLSI$-59M

FCF (TTM)

KROS$-48M

TLSI$-23M

EPS (TTM)

KROS-$4.20

TLSI-$1.01

ROE (TTM)

KROS-2140.0%

TLSI-7902.0%

ROA (TTM)

KROS-1979.0%

TLSI-5499.0%

ROIC (TTM)

KROS-2140.0%

TLSI-1789.0%

Cash

KROS$258M

TLSI$46M

Debt

KROS$0

TLSI$33M

Net Cash/Debt

KROS$258M

TLSI$13M

Current Ratio (TTM)

KROS21.96x

TLSI5.35x

Quick Ratio (TTM)

KROS21.53x

TLSI4.72x

Debt/Equity (TTM)

KROS0.00x

TLSI5.05x

Debt/Assets (TTM)

KROS0.0%

TLSI0.0%

Interest Coverage (TTM)

KROSN/A

TLSIN/A

Net Debt/EBITDA (TTM)

KROS0.00x

TLSI0.00x

Beta

KROS1.20

TLSI0.46

52W Performance

KROS-25.1%

TLSI-16.3%

YTD Performance

KROS-35.5%

TLSI-33.4%

% from 52W High

KROS-47.0%

TLSI-48.9%

% from 52W Low

KROS23.3%

TLSI84.5%

Asset Turnover (TTM)

KROS0.06x

TLSI0.88x

FCF Yield (TTM)

KROS-20.5%

TLSI-9.3%

Earnings Yield (TTM)

KROS-35.2%

TLSI-23.5%

Dividend Yield (TTM)

KROSN/A

TLSIN/A

Rule of 40

KROS-416.5

TLSI-26.4

EV/GP/RG

KROSN/A

TLSI0.11

Ticker research

View KROS research View TLSI research

Metric	KROS Keros Therapeutics Inc	TLSI TriSalus Life Sciences Inc
Market & Valuation
Market Cap	$236M	$249M
Enterprise Value	$-21M	$236M
Price	$11.95	$4.06
P/E Ratio	N/A	N/A
P/S Ratio	15.75x	5.53x
EV/Sales	-1.41x	5.24x
EV/EBITDA	-0.47x	0.00x
P/B Ratio	0.86x	40.61x
P/FCF Ratio	N/A	N/A
EV/FCF	0.44x	-10.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.61x
Revenue & Growth
Revenue (TTM)	$15M	$45M
Revenue Growth (YoY)	-93.6%	25.2%
Forward Rev Growth	-96.3%	40.1%
Profitability
Gross Margin (TTM)	0.0%	85.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-665.2%	-66.4%
Net Margin (TTM)	-553.9%	-130.2%
FCF Margin (TTM)	-322.9%	-51.6%
Net Income (TTM)	$-83M	$-59M
FCF (TTM)	$-48M	$-23M
EPS (TTM)	-$4.20	-$1.01
ROE (TTM)	-2140.0%	-7902.0%
ROA (TTM)	-1979.0%	-5499.0%
ROIC (TTM)	-2140.0%	-1789.0%
Financial Health
Cash	$258M	$46M
Debt	$0	$33M
Net Cash/Debt	$258M	$13M
Current Ratio (TTM)	21.96x	5.35x
Quick Ratio (TTM)	21.53x	4.72x
Debt/Equity (TTM)	0.00x	5.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	0.46
52W Performance	-25.1%	-16.3%
YTD Performance	-35.5%	-33.4%
% from 52W High	-47.0%	-48.9%
% from 52W Low	23.3%	84.5%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.88x
FCF Yield (TTM)	-20.5%	-9.3%
Earnings Yield (TTM)	-35.2%	-23.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-416.5	-26.4
EV/GP/RG	N/A	0.11
Ticker research	View KROS research	View TLSI research

Valuation

P/S Ratio

TLSI

5.53x

KROS

15.75x

EV/FCF

TLSI

-10.14x

KROS

0.44x

Growth & revenue

Revenue Growth TTM

TLSI

25.2%

KROS

-93.6%

Forward Revenue Growth

TLSI

40.1%

KROS

-96.3%

Profitability & performance

Gross Margin

TLSI

85.8%

KROS

0.0%

ROE

KROS

-2140.0%

TLSI

-7902.0%

FCF Yield %

TLSI

-9.3%

KROS

-20.5%

52-Week Performance

TLSI

-16.3%

KROS

-25.1%

Detailed metrics comparison

KROS

Keros Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Market Cap

KROS$236M

TLSI$249M

Enterprise Value

KROS$-21M

TLSI$236M

Price

KROS$11.95

TLSI$4.06

P/E Ratio

KROSN/A

TLSIN/A

P/S Ratio

KROS15.75x

TLSI5.53x

EV/Sales

KROS-1.41x

TLSI5.24x

EV/EBITDA

KROS-0.47x

TLSI0.00x

P/B Ratio

KROS0.86x

TLSI40.61x

P/FCF Ratio

KROSN/A

TLSIN/A

EV/FCF

KROS0.44x

TLSI-10.14x

PEG Ratio

KROSN/A

TLSIN/A

Forward P/E (NTM)

KROSN/A

TLSIN/A

Forward P/S (NTM)

KROSN/A

TLSI3.61x

Revenue (TTM)

KROS$15M

TLSI$45M

Revenue Growth (YoY)

KROS-93.6%

TLSI25.2%

Forward Rev Growth

KROS-96.3%

TLSI40.1%

Gross Margin (TTM)

KROS0.0%

TLSI85.8%

Operating Margin (TTM)

KROS0.0%

TLSI0.0%

EBITDA Margin (TTM)

KROS-665.2%

TLSI-66.4%

Net Margin (TTM)

KROS-553.9%

TLSI-130.2%

FCF Margin (TTM)

KROS-322.9%

TLSI-51.6%

Net Income (TTM)

KROS$-83M

TLSI$-59M

FCF (TTM)

KROS$-48M

TLSI$-23M

EPS (TTM)

KROS-$4.20

TLSI-$1.01

ROE (TTM)

KROS-2140.0%

TLSI-7902.0%

ROA (TTM)

KROS-1979.0%

TLSI-5499.0%

ROIC (TTM)

KROS-2140.0%

TLSI-1789.0%

Cash

KROS$258M

TLSI$46M

Debt

KROS$0

TLSI$33M

Net Cash/Debt

KROS$258M

TLSI$13M

Current Ratio (TTM)

KROS21.96x

TLSI5.35x

Quick Ratio (TTM)

KROS21.53x

TLSI4.72x

Debt/Equity (TTM)

KROS0.00x

TLSI5.05x

Debt/Assets (TTM)

KROS0.0%

TLSI0.0%

Interest Coverage (TTM)

KROSN/A

TLSIN/A

Net Debt/EBITDA (TTM)

KROS0.00x

TLSI0.00x

Beta

KROS1.20

TLSI0.46

52W Performance

KROS-25.1%

TLSI-16.3%

YTD Performance

KROS-35.5%

TLSI-33.4%

% from 52W High

KROS-47.0%

TLSI-48.9%

% from 52W Low

KROS23.3%

TLSI84.5%

Asset Turnover (TTM)

KROS0.06x

TLSI0.88x

FCF Yield (TTM)

KROS-20.5%

TLSI-9.3%

Earnings Yield (TTM)

KROS-35.2%

TLSI-23.5%

Dividend Yield (TTM)

KROSN/A

TLSIN/A

Rule of 40

KROS-416.5

TLSI-26.4

EV/GP/RG

KROSN/A

TLSI0.11

Ticker research

View KROS research View TLSI research

Metric	KROS Keros Therapeutics Inc	TLSI TriSalus Life Sciences Inc
Market & Valuation
Market Cap	$236M	$249M
Enterprise Value	$-21M	$236M
Price	$11.95	$4.06
P/E Ratio	N/A	N/A
P/S Ratio	15.75x	5.53x
EV/Sales	-1.41x	5.24x
EV/EBITDA	-0.47x	0.00x
P/B Ratio	0.86x	40.61x
P/FCF Ratio	N/A	N/A
EV/FCF	0.44x	-10.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	3.61x
Revenue & Growth
Revenue (TTM)	$15M	$45M
Revenue Growth (YoY)	-93.6%	25.2%
Forward Rev Growth	-96.3%	40.1%
Profitability
Gross Margin (TTM)	0.0%	85.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-665.2%	-66.4%
Net Margin (TTM)	-553.9%	-130.2%
FCF Margin (TTM)	-322.9%	-51.6%
Net Income (TTM)	$-83M	$-59M
FCF (TTM)	$-48M	$-23M
EPS (TTM)	-$4.20	-$1.01
ROE (TTM)	-2140.0%	-7902.0%
ROA (TTM)	-1979.0%	-5499.0%
ROIC (TTM)	-2140.0%	-1789.0%
Financial Health
Cash	$258M	$46M
Debt	$0	$33M
Net Cash/Debt	$258M	$13M
Current Ratio (TTM)	21.96x	5.35x
Quick Ratio (TTM)	21.53x	4.72x
Debt/Equity (TTM)	0.00x	5.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.20	0.46
52W Performance	-25.1%	-16.3%
YTD Performance	-35.5%	-33.4%
% from 52W High	-47.0%	-48.9%
% from 52W Low	23.3%	84.5%
Efficiency & Yields
Asset Turnover (TTM)	0.06x	0.88x
FCF Yield (TTM)	-20.5%	-9.3%
Earnings Yield (TTM)	-35.2%	-23.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-416.5	-26.4
EV/GP/RG	N/A	0.11
Ticker research	View KROS research	View TLSI research